1. Introduction {#s0005}
===============

Coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 is a pandemic as of Mar. 2020. Initial reports from China revealed diverse risk factors, clinical courses and outcome for a relatively homogenous population ([@bb0140]). Morbidity and mortality vary between populations ([@bb0130]). African Americans and Latinos are disproportionately affected by COVID-19 and show significantly higher mortality compared to the other race and ethnic groups in the US ([@bb0115]) and in the UK ([@bb0075]). A "healthcare disparity" must be responsible for the high incidence among minorities although socioeconomic factors, underlying medical conditions, and the difference in genetic susceptibility to SARS-CoV-2 infection may contribute ([@bb0020]). Of note, a 3p21.31 gene cluster---*SLC6A20, LZTFL1, CCR9, FYCO1, CXCR6* and *XCR1*---is associated with genetic susceptibility for severe COVID-19 cases with respiratory failure ([@bb0040]). To find allelic variation across populations in the genes that are known be involved in viral entry to the host cells and sensing of viral RNA in host immune cells, we surveyed publicly available databases of genomic variants.

SARS-CoV-2 is an enveloped and positive single-stranded RNA (ssRNA) virus and initiates human cell entry by binding of spike (S) protein present on the viral envelope to angiotensin converting enzyme 2 (ACE2) receptor on the host cells ([@bb0145]). The SARS-CoV S protein/ACE2 interface has been elucidated at the atomic level, and the ACE2 was found to be a key factor of SARS-CoV transmission ([@bb0090]). The binding mode of SARS-CoV-2 receptor binding domain (RBD) to ACE2 is nearly identical to SARS-CoV ([@bb0080]). The S protein is cleaved into S1 and S2 by the type 2 transmembrane serine protease (TMPRSS2) and endosomal cysteine proteases cathepsin B and L (CatB/L) ([@bb0035]). TMPRSS2 is believed to be of utmost importance for SARS-CoV-2 entry into host cells. Recent studies demonstrated that an inhibitor of the protease activity of TMPRSS2---camostat mesylate---attenuated SARS-CoV-2 entry into lung epithelial cells suggesting a promising candidate for potential intervention against COVID-19 ([@bb0045]). The C-terminal domain of S1 subunit is responsible for binding of SARS-CoV-2 to ACE2 and the S2 subunit undergoes a conformational change that result in virus-membrane fusion and entry into the target cell ([@bb0035]). Viral genomic RNA is then released and translated into viral polymerase proteins for viral replication. Innate immune response is the first line of host defense mechanism for SARS-CoV-2 infection. Toll-like receptors recognize the viral RNA -- double-stranded RNA (dsRNA) by TLR3 and ssRNA by TLR7 and TLR8 -- and trigger innate immune responses such as the expression of inflammatory genes for type I interferons and pro-inflammatory cytokines ([@bb0055]; [@bb0060]).

Here we surveyed the genetic variants in functional residues of *ACE2, TMPRSS2, CTSB/L* (CatB/L), and *TLR3/7/8* to investigate the difference in the genetic predisposition to the susceptibly of SARS-CoV-2 infection and the initiation of innate immune response. For ACE2, we investigated genetic variants in the residues on the interface to SARS-CoV-2 RBD from recent structural analyses ([@bb0050]; [@bb0080]; [@bb0105]; [@bb0120]; [@bb0125]). Given the high sequence similarity between S proteins of SARS-CoV-2 and SARS-CoV, we also investigated the residues shown to inhibit interactions from in vitro mutagenesis analysis ([@bb0090]). We checked two residues reported to cause loss of cleavage activity of TMPRSS2 ([@bb0005]) and the enzymatically active sites for CatB/L. A total of 16 residues of TLR7 that are necessary for ssRNA-induced activation ([@bb0135]) and the residues affecting reaction to ssRNAs from in vitro mutagenesis studies for TLR3 ([@bb0010]; [@bb0015]; [@bb0100]) and for TLR8 ([@bb0110]) were checked for sequence variation. Additionally, we searched for nonsynonymous variants that would cause loss of gene function (i.e., frameshift, in-frame insertion/deletion, stop-gain, splice-disrupting, start-lost and stop-lost). The list of reported genetic variants in the genes and their allele frequencies (AFs) were compiled from three population-scale genomic variants databases--- gnomAD ([@bb0070]), Korean Reference Genome Database ([@bb0065]), and TogoVar (a Japanese genetic variation database available at <https://togovar.biosciencedbc.jp/>) ---and three whole-genome sequencing datasets (i.e., 1000 Genomes Project ([@bb0025]), Gene-Tissue Expression ([@bb0030]), and Simons Genome Diversity Project ([@bb0095])).

*ACE2* is highly conserved with few nonsynonymous variants in the interacting domain with the SARS-CoV-2 RBM ([@bb0080]). Of 370 coding variants in *ACE2*, 248 were nonsynonymous variants with the highest AF of 1.6% (rs41303171). Within 33 residues interfacing the SARS-CoV-2 RBM, 19 variants (including 4 synonymous variants) were found with average AF of 0.03% (ranges 0--0.39%) ([Table 1](#t0005){ref-type="table"} ). Only one of the 19 variants (rs4646116; K26R) had global AF greater than 0.1% (AF = 0.39%). Rs4646116 (NC_000023.10:g.15618958 T \> C) had the largest AF difference across populations: the lowest AF (0.007%) in East Asian and the highest (0.59%) in Non-Finnish European. The impact of this variant is not yet investigated with structural analysis but was not classified as deleterious (of possible impact on the structure and function of the protein) by in silico prediction algorithms such as SIFT and Polyphen2. The other variants were either very rare (i.e., population AF \< 0.1%) or unique to a population or two. For the five known residues---K31, E35, D38, M82 and K353---that were reported to significantly change binding affinity to viral S protein ([@bb0085]), we found three variants: rs758278442 (K31K), rs1348114695 (E35K), and rs766996587 (M82I). However, all three were either synonymous or predicted to have little impact on protein. Rs758278442 showed significant AF difference across populations, especially among east Asian populations. It is found only among east Asian individuals in gnomAD -- consists of 1909 Korean, 76 Japanese, and 7212 other east Asian individuals -- with AF of 0.022%. The variant is also found at Korean Reference Genome Database (*N* = 1722) with AF of 0.029%, similar value to gnomAD. However, it was found with higher AF of 0.23% at Japanese genetic variation database (*N* = 3552). Rs1348114695 at residue 35 was found only in European and east Asian populations with very low frequencies: 0.001% and 0.014%, respectively. Lastly, rs766996587 at residue 82 was found only in African population (AF = 0.026%). Nonetheless, protein modeling predicts little topological difference between all ACE2 variants and wild-type ACE in their binding to S protein ([@bb0050]). Therefore, we expect minimal genetic variance across populations critically affecting interaction between ACE2 and SARS-CoV-2. [Fig. 1](#f0005){ref-type="fig"}A illustrates the 19 variants over known functional protein domains of ACE2.Table 1Genetic variants in the genes related to host-viral interaction and sensing of viral RNAs.Table 1GenesResiduesAA changes from mutagenesis studiesResidue loci (b37)Reported variants within the residuesVariant allele frequenciesVariantsRS IDImpactAA ChangegnomAD^\[1\]^1KGP^\[2\]^SGDP^\[3\]^GTEx^\[4\]^KRGDB^\[5\]^TogoVar^\[6\]^GlobalAfricanLatinoEuropeanEast AsianSouth AsianACE2S19^\[7,10\]^X:15618978--15,618,980NC_000023.10:g.15618980A \> Grs73635825MissenseS \> P0.031%0.332%A25^\[11\]^24--26, QAK-KAEX:15618957--15,618,965NC_000023.10:g.15618960G \> Ars761614932Synonymous=0.001%0.007%0.030%K26^\[11\]^NC_000023.10:g.15618958 T \> Crs4646116MissenseK \> R0.388%0.095%0.325%0.587%0.007%0.131%0.210%0.333%0.477%NC_000023.10:g.15618959 T \> Crs1299103394MissenseK \> E0.001%0.001%T27^\[7,9\]^X:15618954--15,618,956NC_000023.10:g.15618956 T \> Crs781255386MissenseT \> A0.001%0.007%K31^\[7,9--11\]^K31DX:15618942--15,618,944NC_000023.10:g.15618942C \> Trs758278442Synonymous=0.002%0.022%0.333%0.029%0.230%H34^\[7--10\]^X:15618933--15,618,935NC_000023.10:g.15618933G \> Ars368655410Synonymous=0.063%0.033%0.027%0.026%0.040%E35^\[7,9,10\]^X:15618930--15,618,932NC_000023.10:g.15618932C \> Trs1348114695MissenseE \> K0.002%0.001%0.014%E37^\[7,9,10\]^X:15618924--15,618,926NC_000023.10:g.15618926C \> Trs146676783MissenseE \> K0.004%0.011%0.333%K68^\[11\]^K68DX:15613109--15,613,111NC_000023.10:g.15613111 T \> Crs755691167MissenseK \> E0.001%0.011%M82^\[7--11\]^82--84, MYP-NFSX:15613061--15,613,069NC_000023.10:g.15613067C \> Trs766996587MissenseM \> I0.002%0.026%P84^\[11\]^NC_000023.10:g.15613063G \> Trs759134032MissenseP \> T0.001%0.005%E329^\[7\]^X:15599427--15,599,429NC_000023.10:g.15599428 T \> Crs143936283MissenseE \> G0.003%0.007%D355^\[7,9,11\]^D355AX:15599349--15,599,351NC_000023.10:g.15599351C \> Trs961360700MissenseD \> N0.001%0.003%P389^\[11\]^P389AX:15596342--15,596,344NC_000023.10:g.15596343G \> Trs762890235MissenseP \> H0.004%0.018%0.002%P426^\[11\]^425--427, SPD-PSNX:15596228--15,596,236NC_000023.10:g.15596233G \> Crs1238146879MissenseP \> A0.001%0.001%NC_000023.10:g.15596231G \> Ars1335386721Synonymous=0.001%0.001%D427^\[11\]^NC_000023.10:g.15596230C \> Ars1316056737MissenseD \> Y0.001%0.015%R559^\[11\]^R559SX:15589907--15,589,909NC_000023.10:g.15589907C \> Grs1016777825MissenseR \> S0.001%0.004%TLR7^\[12\]^F351F351AX:12904678--12,904,680NC_000023.10:g.12904680 T \> Crs200549906Synonymous=0.002%0.004%L557L557AX:12905296--12,905,298NC_000023.10:g.12905296C \> Trs1419393304MissenseL \> F0.002%0.001%T586T586AX:12905383--12,905,385NC_000023.10:g.12905385 T \> Ars185622718Synonymous=0.001%0.007%0.030%L105L105AX:12903940--12,903,942NC_000023.10:g.12903940C \> Trs773554481Synonymous=0.001%0.001%D135D135AX:12904030--12,904,032NC_000023.10:g.12904032 T \> Crs769401373Synonymous=0.033%0.458%0.050%R186R186AX:12904183--12,904,185NC_000023.10:g.12904184G \> Ars868177091MissenseR \> Q0.001%0.005%R473R473AX:12905044--12,905,046NC_000023.10:g.12905045G \> Ars754381606MissenseR \> K0.001%0.005%CTSB (CatB)^\[13\]^C1088:11708378--11,708,380NC_000008.10:g.11708378G \> Ars759843078Synonymous=0.002%0.013%H2788:11703258--11,703,260NC_000008.10:g.11703259 T \> Crs1373655221MissenseH \> R0.0004%Only found in Finnish population (0.005%)NC_000008.10:g.11703260G \> Ars1225109229MissenseH \> Y0.0004%0.001%CTSL (CatL)^\[14\]^C1389:90343515--90,343,517NC_000009.11:g.90343515 T \> Crs757571238MissenseC \> R0.001%0.003%TLR3^\[15\]^H539H539E4:187004455--187,004,457NC_000004.11:g.187004456A \> Grs776387492MissenseH \> R0.001%0.005%0.003%0.029%Y759Y759F4:187005115--187,005,117NC_000004.11:g.187005115 T \> Crs768605211MissenseY \> H0.001%0.007%TLR8^\[16\]^Y348Y348AX:12938201--12,938,203NC_000023.10:g.12938202A \> Grs1175381548MissenseY \> C0.001%Only found in Finnish population (0.006%)NC_000023.10:g.12938203 T \> Crs768875789Synonymous=0.001%0.007%[^2][^3][^4][^5][^6][^7][^8][^9][^10][^11][^12][^13][^14][^15][^16][^17]Fig. 1Location of genetic variants relative to known functional domains of (A) ACE2, (B) CTLB/L and (C) TLR3/7/8. For each gene, x-axis represents positions in protein sequence. The block diagram directly above the x-axis depicts major protein domains in different colored boxes. The vertical red lines above domains correspond to the critical residues investigated in this study. Each of the circles with grey lines represents variant found on the critical loci. The circles are colored differently based on their calculated effect on protein: loss-of-function (LoF) variants (red), missense variants (orange), and synonymous variants (green). The height of each circle denotes variant allele frequency (in -log10 scale). The higher the circle, the lower the allele frequency. Of note, TMPRSS2 does not have any reported genetic variant in enzymatically active functional domain. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)Fig. 1

The proteolysis activity of TMPRSS2 is crucial for viral entry to host cells ([@bb0045]). Two residues, V292 and M478, are reported to impact the catalytic activity of TMPRSS2 ([@bb0005]) but we found no variants at these residues ([Supplementary Table 1](#ec0005){ref-type="supplementary-material"}). Reported variants for *TMPRSS2* contain 417 nonsynonymous variants including 40 loss-of-function variants. All of loss-of-function variants were very rare (AF \< 0.01%). The rest of nonsynonymous variants were also of low frequencies (AF \< 0.1%) mostly. Of the only 5 nonsynonymous variants with AF \> 0.1%, rs12329760 (V192M, global AF = 24.88%) predicted deleterious and its AF ranged from 15.33% (Latino) to 38.38% (East Asian). Further studies are required to test whether rs12329760 could exert functional impact on TMPRSS2 activity. Thus, differences in TMPRSS2 activity caused either by variants at critical loci or by loss-of-function variants are unlikely. SARS-CoV-2 uses both TMPRSS2 and the endosomal cysteine proteases cathepsin B and L (CTSB and CTSL) for priming S protein ([@bb0045]). UniProt entries for human CTSB and CTSL report 3 active sites. We found 3 variants in the active sites for CTSB (two missense variants and one synonymous variant), and one missense variant for CTSL ([Table 1](#t0005){ref-type="table"} and [Fig. 1](#f0005){ref-type="fig"}B). Although all missense variants on active sites of CTSB/L are predicted deleterious, they were of very low allele frequencies (AF \< 0.01%). *CTSB* has 429 nonsynonymous variants including 51 loss-of-function variants (all with AF \< 0.01%). *CTSL* has 211 nonsynonymous variants including 17 loss-of-function variants. Of note, one of 17 variants in *CTSL* (rs2378757, NC_000009.11:g.90343780A \> C) is a common allele (global AF of 70.32%, population AF ranges from 62.66% to 98.48%). The variant changes stop codon to serine for one *CTSL* transcript isoform (ENST00000342020.5) but falls in intron for the other transcript isoforms.

Next we checked genetic variants in TLRs that sense viral RNAs and initiate innate immune responses. There were 7 variants---4 synonymous and 3 nonsynonymous---in the 16 residues of ssRNA interacting domain of TLR7 ([Table 1](#t0005){ref-type="table"} and [Fig. 1](#f0005){ref-type="fig"}C). Most variants were of extremely low frequencies (AF \< 0.01%) except for one synonymous variant, rs769401373 (D135D), found only in east Asian population (AF = 0.46%). *TLR7* harbors 232 nonsynonymous variants including 8 loss-of-function variants. As in *TMPRSS2*, AFs of loss-of-function variants were also very low (AF \< 0.01%). The UniProt entries for TLR3 and TLR8 list 10 sites (6 for TLR3 ([@bb0010]; [@bb0015]; [@bb0100]) and 4 for TLR8 ([@bb0110])) from in vitro mutagenesis study that impact their response to viral infection (sensing of dsRNA or ssRNA, respectively). For these loci, two missense variants on *TLR3* and one missense variant with one synonymous variant on *TLR8* were found ([Table 1](#t0005){ref-type="table"} and [Fig. 1](#f0005){ref-type="fig"}C). All of these variants in *TLRs* were very rare (AF \< 0.01%) across all populations.

To summarize, the critical loci for host-viral interaction and sensing viral genomic RNA are highly conserved in all populations with few very rare variants. Especially, *ACE2* and *TLR7* seem to be under strong selection pressure as reflected in their relatively lower number of loss-of-function variants than expected in large variant databases such as gnomAD ([@bb0070]): three observed variants out of 31 expected ones for *ACE2* and two observed variants out of 20.7 expected ones for *TLR7*. Moreover, nonsynonymous variants in these genes were mostly of very low frequencies which suggests the chance of gene function altered by these variants would be unlikely, compared to the incidence of COVID-19 around the globe. Other factors such as existing medical conditions and environmental risk factors could contribute the regulation of expression of these key genes in susceptible individuals; however, further studies are required to elucidate potential associations.

The majority of infected individuals experience no or mild symptoms of upper respiratory tract infection; however, for some individuals, the consequence of SARS-CoV-2 infection could be fatal. One of the contributing factors may be the viral load due to differential affinity of viral spike proteins to ACE2 and the efficiency of cleavage by TMPRSS2 that are essential for virus to enter and replicate inside of host cells. We did not find genetic variation between populations while there is a significant difference in incidence and mortality between race and ethnic groups in the U.S. Therefore, underlying medical conditions, age, environmental factors (e.g., air pollution, smoking, and humidity), and a healthcare disparity influence morbidity and mortality from COVID-19 considering the allelic spectrum for the key genes associated with viral entry. Nonetheless, genetic susceptibility may play a role for severe cases with respiratory failure ([@bb0040]).

The population-scale genotype databases and datasets used in this study have limitations from relatively small sample size and imbalanced and incomplete representation of various human populations. Thus, there could be unreported variants in *ACE2, TMPRSS2*, and *TLR3/7/8* that may be associated with change of susceptibility to COVID-19. With additional population-scale genomic databases for diverse populations, it will be possible to identify the individuals with rare genetic variants such as rs758278442 in the interacting domain of ACE2 and the genetic predisposition to cytokine storm that causes an acute progress of illness in young people. In parallel, a systematic mutagenesis analysis of the RBM of ACE2 is highly required to understand the difference in host-viral interaction across populations ([@bb0080]).

The following are the supplementary data related to this article.Supplementary Table 1Important loci and genetic variants in the genes related to host-viral interaction and sensing of viral RNA.Supplementary Table 1
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